Canterbury DHB



AIDA Protocol:

Continue tretinoin if marrow appearances are equivocal at day 30. If HCR is not achieved by 60 days, take the patient off the study and consider other treatment such as arsenic.

About this Canterbury DHB document (4367):

Document Owner:

Blake Hsu (see Who's Who)

Last Reviewed:

October 2018

Next Review:

October 2020


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 4367